Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Uliledlimab

Copy Product Info
😃Good
Catalog No. T76730Cas No. 2378407-27-1
Alias TJ-004309, TJ004309

Uliledlimab is a humanized monoclonal antibody with potent inhibitory activity against CD73, the ecto-5'-nucleotidase enzyme that catalyzes the conversion of extracellular AMP to adenosine. Uliledlimab reduces extracellular adenosine production, thereby modulating immunosuppressive pathways. Uliledlimab holds significant potential for use in immuno-oncology and cancer research.

Uliledlimab

Uliledlimab

Copy Product Info
😃Good
Purity: 95%
Catalog No. T76730Alias TJ-004309, TJ004309Cas No. 2378407-27-1
Uliledlimab is a humanized monoclonal antibody with potent inhibitory activity against CD73, the ecto-5'-nucleotidase enzyme that catalyzes the conversion of extracellular AMP to adenosine. Uliledlimab reduces extracellular adenosine production, thereby modulating immunosuppressive pathways. Uliledlimab holds significant potential for use in immuno-oncology and cancer research.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$339-In Stock
5 mg$730-In Stock
10 mg$1,160-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:95.5% (SDS-PAGE); 95.1% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Uliledlimab is a humanized monoclonal antibody with potent inhibitory activity against CD73, the ecto-5'-nucleotidase enzyme that catalyzes the conversion of extracellular AMP to adenosine. Uliledlimab reduces extracellular adenosine production, thereby modulating immunosuppressive pathways. Uliledlimab holds significant potential for use in immuno-oncology and cancer research.
In vitro
Uliledlimab completely inhibits the enzymatic activity of CD73 by binding to the C-terminal domain of the CD73 protein broussonetia papyrifera. By blocking adenosine production, Uliledlimab alleviates immune cell suppression, enhances the activity of CD8+ T cells and macrophages, and ultimately strengthens the anti-tumor immune response [1].
In vivo
Uliledlimab, when used alone or in combination with the PD-L1 inhibitor Atezolizumab, can effectively inhibit the growth of solid tumors [1].
SynonymsTJ-004309, TJ004309
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetNT5E/CD73
Chemical Properties
Molecular Weight145.02 kDa
Cas No.2378407-27-1
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Uliledlimab | purchase Uliledlimab | Uliledlimab cost | order Uliledlimab | Uliledlimab in vivo | Uliledlimab in vitro | Uliledlimab molecular weight